Jérôme Avouac Selected Research

Collagen

8/2023	Effects of B Cell Depletion by CD19-Targeted Chimeric Antigen Receptor T Cells in a Murine Model of Systemic Sclerosis.
1/2022	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.
5/2015	Systemic sclerosis: Recent insights.
11/2014	The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
3/2014	Targeted immunotherapies in systemic sclerosis.
5/2012	Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jérôme Avouac Research Topics

Disease

31	Systemic Scleroderma (Systemic Sclerosis) 12/2023 - 03/2011
21	Rheumatoid Arthritis 01/2024 - 02/2014
20	Fibrosis (Cirrhosis) 08/2023 - 03/2011
9	Inflammation (Inflammations) 12/2023 - 03/2011
8	Interstitial Lung Diseases (Interstitial Lung Disease) 12/2023 - 01/2018
8	COVID-19 08/2023 - 01/2021
7	Rheumatic Diseases (Rheumatism) 08/2023 - 03/2014
6	Arthritis (Polyarthritis) 08/2023 - 07/2013
6	digital ulcers 01/2022 - 03/2010
6	Pulmonary Hypertension 01/2018 - 07/2015
4	Autoimmune Diseases (Autoimmune Disease) 08/2023 - 03/2011
4	Infections 08/2023 - 01/2022
4	Connective Tissue Diseases (Connective Tissue Disease) 08/2023 - 05/2015
4	Vascular Remodeling 01/2022 - 11/2011
4	Neoplasms (Cancer) 11/2021 - 03/2008
4	Diffuse Scleroderma (Progressive Systemic Sclerosis) 07/2021 - 04/2010
4	Disease Progression 11/2020 - 01/2016
3	Pain (Aches) 12/2023 - 01/2007
3	Synovitis 01/2023 - 01/2016
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 07/2009
3	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2023 - 05/2012
3	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2018 - 01/2014
3	Hypoxia (Hypoxemia) 01/2016 - 08/2011
2	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 01/2023 - 12/2014
2	Venous Thromboembolism 01/2023 - 12/2022
2	Necrosis 01/2022 - 01/2021
2	Hypertension (High Blood Pressure) 06/2021 - 12/2020
2	Heart Failure 11/2019 - 01/2014
2	Bronchiolitis Obliterans Syndrome 01/2018 - 12/2016
2	Immune System Diseases (Immune Disorders) 01/2016 - 05/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2024
1	Cryoglobulinemia 12/2023
1	Vasculitis (Vasculitides) 08/2023
1	Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis) 08/2023
1	Monoclonal Gammopathy of Undetermined Significance 08/2023
1	Diabetes Mellitus 05/2023
1	Lupus Nephritis 02/2023
1	Axial Spondyloarthritis 01/2023
1	Ulcerative Colitis 01/2023
1	Crohn Disease (Crohn's Disease) 01/2023
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2023

Drug/Important Bio-Agent (IBA)

13	Biomarkers (Surrogate Marker)IBA 01/2023 - 03/2008
9	Rituximab (Mabthera)FDA Link 12/2023 - 10/2014
8	Bleomycin (Blenoxane)FDA LinkGeneric 01/2020 - 03/2011
7	AntibodiesIBA 12/2023 - 12/2014
6	CollagenIBA 08/2023 - 05/2012
5	Janus Kinase InhibitorsIBA 12/2023 - 01/2021
5	Abatacept (Orencia)FDA Link 01/2021 - 07/2013
4	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2020 - 05/2012
3	Methotrexate (Mexate)FDA LinkGeneric 12/2023 - 01/2022
3	C-Reactive ProteinIBA 12/2023 - 12/2020
3	tocilizumab (atlizumab)FDA Link 08/2023 - 07/2013
3	Anti-Citrullinated Protein AntibodiesIBA 07/2023 - 12/2014
3	Interleukin-6 (Interleukin 6)IBA 01/2023 - 07/2014
3	Brain Natriuretic Peptide (Natrecor)FDA Link 11/2016 - 02/2014
3	erucylphosphocholineIBA 04/2013 - 11/2011
2	baricitinibIBA 12/2023 - 07/2021
2	Rheumatoid FactorIBA 12/2023 - 01/2023
2	tixagevimabIBA 08/2023 - 12/2022
2	cilgavimabIBA 08/2023 - 12/2022
2	Chimeric Antigen ReceptorsIBA 08/2023 - 11/2021
2	Antirheumatic Agents (DMARD)IBA 08/2023 - 01/2021
2	omega-Chloroacetophenone (Mace)IBA 05/2023 - 01/2023
2	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2023 - 06/2021
2	Semaphorins (Semaphorin)IBA 01/2023 - 01/2021
2	Monoclonal AntibodiesIBA 12/2022 - 06/2013
2	nintedanibIBA 01/2022 - 10/2021
2	AutoantibodiesIBA 01/2022 - 10/2015
2	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2020 - 01/2019
2	Carbon MonoxideIBA 01/2019 - 01/2014
2	pro-brain natriuretic peptide (1-76)IBA 07/2015 - 02/2014
2	TroponinIBA 07/2015 - 02/2014
2	CD226 antigenIBA 01/2015 - 06/2013
2	indium-bleomycinIBA 11/2014 - 06/2014
2	CytokinesIBA 07/2014 - 03/2014
2	Hydroxyproline (4 Hydroxyproline)IBA 06/2013 - 03/2011
1	Lenalidomide (CC 5013)FDA Link 01/2024
1	Prostaglandins AIBA 12/2023
1	Arsenic Trioxide (Trisenox)FDA Link 12/2023
1	Janus KinasesIBA 12/2023
1	SS-A antibodiesIBA 12/2023
1	CarbonIBA 12/2023
1	RNA (Ribonucleic Acid)IBA 12/2023
1	4- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA 08/2023
1	Immunosuppressive Agents (Immunosuppressants)IBA 08/2023
1	sarilumabIBA 01/2023
1	amsonic acid (DAS)IBA 01/2023
1	Immunomodulating AgentsIBA 01/2023
1	Inosine Triphosphate (ITP)IBA 01/2023
1	cilgavimab and tixagevimab drug combinationIBA 12/2022
1	VaccinesIBA 12/2022
1	anti-scl-70 autoantibodiesIBA 11/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Hypochlorous Acid (Hypochlorite)IBA 01/2022

Therapy/Procedure

17	Therapeutics 12/2023 - 03/2008
3	Immunotherapy 06/2017 - 03/2014
2	Biological Therapy 01/2022 - 03/2014
1	Secondary Prevention 12/2022
1	Aftercare (After-Treatment) 12/2022
1	Injections 01/2022